Molecular characterization of genomic breakpoints of ALK rearrangements in non‐small cell lung cancer

ALK rearrangement is called the ‘diamond mutation’ in non‐small cell lung cancer (NSCLC). Accurately identifying patients who are candidates for ALK inhibitors is a key step in making clinical treatment decisions. In this study, a total of 783 ALK rearrangement‐positive NSCLC cases were identified b...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zizong, Han, Yushuai, Tao, Houquan, Xu, Mengxiang, Liu, Zhengchuang, Zhu, Jianhua, Li, Wei, Ma, Jie, Liu, Zhifang, Wang, Weiran, Ma, Tonghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158786/
https://www.ncbi.nlm.nih.gov/pubmed/36423218
http://dx.doi.org/10.1002/1878-0261.13348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158786/
https://www.ncbi.nlm.nih.gov/pubmed/36423218
http://dx.doi.org/10.1002/1878-0261.13348

Ejemplares similares